Comparison of hepatic arterial infusion chemotherapy and sorafenib in elderly patients with advanced hepatocellular carcinoma: A case series
Comparison of hepatic arterial infusion chemotherapy and sorafenib in elderly patients with advanced hepatocellular carcinoma: A case series
复制标题
DOI：
10.3892/mco.2014.371
复制
发表时间：
2014-11-01
影响因子：
1.2
通讯作者：
Nakamoto, Yasunari
中科院分区：
文献类型：
--
作者：
Nemoto, Tomoyuki;Matsuda, Hidetaka;Nakamoto, Yasunari
索拉非尼和肝动脉灌注化疗（HAIC）均适用于不可切除的肝细胞癌（HCC）。在这项研究中，我们比较了 HAIC 与索拉非尼在老年 HCC 患者中的疗效和安全性。符合资格的患者包括年龄≥70岁、经组织学或临床证实患有晚期HCC的患者。共有 12 名患者接受索拉非尼（每天 800 mg）治疗，8 名患者接受 HAIC 联合 5-氟尿嘧啶（第 1-5 天和第 8-12 天为 300 mg/m(2)），联合或不联合顺铂（第 1 天和 8 天为 20 mg/m(2)），联合干扰素-a（每周 3 次，持续 4 周）。与接受索拉非尼治疗的患者（无反应）相比，接受 HAIC 治疗的患者的反应率（37.5%）显着更高。索拉非尼组和 HAIC 组的中位总生存期（18.6 个月和 11.7 个月）和无进展生存期（4.0 个月和 5.0 个月）分别相似。在索拉非尼组中，58.3% 的患者停止治疗，而 HAIC 组则没有。导致索拉非尼停药的最常见不良事件是厌食症。与索拉非尼类似，HAIC 似乎是一种可行的治疗方法，并且对于患有晚期 HCC 的老年患者也可能具有足够的安全性。需要在更多的老年患者中进一步研究 HAIC，以评估其作为索拉非尼替代方案治疗 HCC 的潜力。
Sorafenib and hepatic arterial infusion chemotherapy (HAIC) are both indicated for unresectable hepatocellular carcinoma (HCC). In this study, we compared the efficacy and safety of HAIC to that of sorafenib in elderly patients with HCC. Eligible patients included those aged >= 70 years, with histologically or clinically confirmed advanced HCC. A total of 12 patients received sorafenib (800 mg per day) and 8 patients received HAIC with 5-fluorouracil (300 mg/m(2) on days 1-5 and 8-12) with or without cisplatin (20 mg/m(2) on days 1 and 8), with interferon-a (3 times per week for 4 weeks). The response rate was significantly higher in patients treated with HAIC (37.5%) compared to that in patients treated with sorafenib (no response). The median overall survival (18.6 and 11.7 months) and progression-free survival (4.0 and 5.0 months) were similar between the sorafenib and HAIC groups, respectively. In the sorafenib group, 58.3% of the patients discontinued treatment compared to none in the HAIC group. The most frequent adverse event leading to discontinuation of sorafenib was anorexia. Similar to sorafenib, HAIC appears to be a feasible treatment and may also have the advantage of an adequate safety profile for elderly patients with advanced HCC. Further study of HAIC in a larger population of elderly patients is required to assess its potential as an alternative to sorafenib for HCC.